Press Releases - 2023-11-20

Date	Title	Company
20-Nov-2023	MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction	MorphoSys AG
20-Nov-2023	Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction	MorphoSys AG
20-Nov-2023	Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)	Astex Pharmaceuticals
20-Nov-2023	Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment	Landmark medicines
20-Nov-2023	Pistoia Alliance Sets Out Strategic Priorities to Accelerate Sustainability, Adoption of AI, and use of FAIR and Real-World Data in R&D	Pistoia Alliance
20-Nov-2023	“Inizio Launch Elevate” Set to Help Global Pharma Maximize Product Launch Potential	Inizio
20-Nov-2023	Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis	Chiesi Group
20-Nov-2023	Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis	Chiesi Group
20-Nov-2023	Hovione acquires ExtremoChem and its portfolio of proprietary sugars to support customers with stabilization and delivery of biopharmaceuticals	Hovione
20-Nov-2023	Global Wearable Blood Pressure Monitor Industry Surging to US$ 8 Billion by 2032, at a ranging CAGR from 15% to 16% \| FMI Analysis	MARKITWIRED
20-Nov-2023	Global Paediatric Influenza Treatment Industry Set to Surge to US$ 847.7 Million by 2032, at a CAGR of 3.5% \| FMI Analysis	MARKITWIRED
20-Nov-2023	Global Ocular Tuberculosis Therapeutics Industry Eyes a Remarkable US$753.2 Million Valuation by 2032, Driven by a 5.8% CAGR \| FMI Analysis	MARKITWIRED
20-Nov-2023	Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference	Mainz BioMed N.V.
20-Nov-2023	Global Cardiometabolic Drugs Industry Expected to Surpass US$ 70 Billion, at a CAGR of 4% to 5% between 2022 and 2032	MARKITWIRED
20-Nov-2023	Global Serum Separation Gels Industry Anticipates Robust Growth, Forecasted to Reach US$ 12.39 Billion by 2032 with a 5% CAGR	MARKITWIRED
20-Nov-2023	Global Pancreatic Stone Protein Testing Industry Poised for Rapid Growth, Projected to Reach US$ 3.59 Billion by 2032 with a 1.8% CAGR \| FMI	MARKITWIRED
20-Nov-2023	Global Peptide Receptor Radionuclide Therapy (PRRT) Industry Poised for Remarkable Growth, Projected to Reach US$ 1.3 Billion by 2033 \| FMI	MARKITWIRED
20-Nov-2023	Global Next Generation Infusion Pump Industry to Attain US$ 8.5 Billion by 2032 with a 4.8% CAGR \| FMI Insights	MARKITWIRED
20-Nov-2023	Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052	Drägerwerk AG & Co. KGaA
20-Nov-2023	Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000	Tryp Therapeutics Inc.